These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16617873)

  • 1. [The efficacy of Gosyajinkigan for pollakisuria].
    Watanabe A; Akashi T; Fujiuchi Y; Mizuno I; Nagakawa O; Fuse H
    Hinyokika Kiyo; 2006 Mar; 52(3):197-201. PubMed ID: 16617873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of Goshajinkigan on storage symptoms in prostatic disease--fundamental researches of Chinese herbal medicine for voiding dysfunction and its future aspects].
    Fujiuchi Y; Watanabe A; Fuse H
    Hinyokika Kiyo; 2008 Jun; 54(6):463-6. PubMed ID: 18634447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
    Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
    Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kampo preparations for prostatic hyperplasia: usefulness of Saireito for nocturia].
    Sugiyama T; Oonishi N; Onoe M; Kurita T
    Hinyokika Kiyo; 2002 Jun; 48(6):343-6. PubMed ID: 12166233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
    Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
    Ishizaka K; Machida T; Tanaka M; Kawamura N; Nakamura K; Kihara K
    Int J Urol; 2009 Mar; 16(3):299-302. PubMed ID: 19207610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
    Paick JS; Ku JH; Shin JW; Yang JH; Kim SW
    BJU Int; 2006 May; 97(5):1017-23. PubMed ID: 16643483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
    Ukimura O; Kanazawa M; Fujihara A; Kamoi K; Okihara K; Miki T;
    Int J Urol; 2008 Dec; 15(12):1049-54. PubMed ID: 19120513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms.
    Noguchi M; Kakuma T; Tomiyasu K; Yamada A; Itoh K; Konishi F; Kumamoto S; Shimizu K; Kondo R; Matsuoka K
    Asian J Androl; 2008 Sep; 10(5):777-85. PubMed ID: 18097505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.